"Serogroup" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A set of variants within a species of microorganisms that are antigenically, closely related. With bacteria, a serogroup refers to a group that shares a common antigen.
| Descriptor ID |
D065288
|
| MeSH Number(s) |
G05.695.825
|
| Concept/Terms |
Serotype- Serotype
- Serotypes
- Serovar
- Serovars
|
Below are MeSH descriptors whose meaning is more general than "Serogroup".
Below are MeSH descriptors whose meaning is more specific than "Serogroup".
This graph shows the total number of publications written about "Serogroup" by people in this website by year, and whether "Serogroup" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 3 | 4 |
| 2015 | 1 | 3 | 4 |
| 2016 | 1 | 7 | 8 |
| 2017 | 1 | 7 | 8 |
| 2018 | 0 | 3 | 3 |
| 2019 | 2 | 7 | 9 |
| 2020 | 1 | 5 | 6 |
| 2021 | 0 | 5 | 5 |
| 2022 | 1 | 6 | 7 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 5 | 6 |
| 2025 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serogroup" by people in Profiles.
-
Molecular Epidemiology of Invasive Group B Streptococcus in South Africa, 2019-2020. J Infect Dis. 2025 Apr 15; 231(4):e697-e707.
-
Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project. J Infect. 2025 Mar; 90(3):106426.
-
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
-
Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis. 2025 Apr; 25(4):457-470.
-
Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):1011-1019.
-
Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children. Nat Commun. 2024 Sep 27; 15(1):8401.
-
Genomic insights into the 2022-2023Vibrio cholerae outbreak in Malawi. Nat Commun. 2024 Jul 26; 15(1):6291.
-
Geographical migration and fitness dynamics of Streptococcus pneumoniae. Nature. 2024 Jul; 631(8020):386-392.
-
Distributions of candidate vaccine Targets, virulence Factors, and resistance features of invasive group B Streptococcus using Whole-Genome Sequencing: A Multicenter, population-based surveillance study. Vaccine. 2024 Jun 11; 42(16):3564-3571.
-
Nanofluidic qPCR unable to detect and serotype Streptococcus pneumoniae in urine samples of hospitalized South African patients with community-acquired pneumonia. Sci Rep. 2023 12 04; 13(1):21332.